Complex diseases such as interstitial lung disease and pulmonary fibrosis requires a collaborative effort to effectively characterize, appropriately diagnose, and efficient evaluate novel therapies. Similarly, basic, translational and clinical research in this field requires the integration of clinical phenotypes with biologic specimens. We propose the expanded development of the Care Center Network and Patient Registry ...more »
What is the relationship of ChILD disorders to other clinical populations that manifest ILD?
What is the relationship of ChILD disorders to more common childhood respiratory diseases?
Can a multipronged approach to reversing/repairing scar tissue in pulmonary fibrosis be deployed as soon as possible?
Does the treatment of gastroesophageal reflux disease improve outcomes in patients with IPF?
Does prednisone therapy improve outcomes in acute exacerbation of IPF?
What is the natural history of the best characterized ChILD disorders (surfactantrelated sequence variants, neuroendocrine cell hyperplasia of infancy (NEHI),pulmonary interstitial glycogenosis (PIG),idiopathic pulmonary hemosiderosis)?
Is FVC a valid surrogate for mortality in patients with idiopathic pulmonary disease?
What is the relationship of ChILD disorders to adult diffuse lung disease?
Do the non-pharmacological interventions of pulmonary rehabilitation and supplemental oxygen for exertional hypoxemia improve quality of life and functional status in patients with chronic fibrotic ILD?